They seem to be mostly effective, albeit still giving less of an immune response than would be possible.

Also Curevac is working together with GSK on a multi mutant mRNA vaccine. Since the mRNA approach seems to be flexible it's reasonable to assume this will allow quick adaptations like this.

https://www.curevac.com/en/2021/02/03/gsk-and-curevac-to-dev...